Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 30 peer-reviewed journal articles Updated
Infectious Disease · HIV infection

Standard of Care: Antiretroviral Therapy (ART)

At a Glance

Antiretroviral therapy (ART) is the standard treatment for HIV, including advanced HIV called AIDS. It suppresses the virus and protects the immune system. Most people start promptly, but cryptococcal or tuberculosis meningitis can require carefully timed treatment.

Antiretroviral Therapy (ART) is the standard treatment for HIV. It is not a cure, but it is a highly effective way to control the virus, protect your immune system, and allow you to live a long, healthy life [1][2]. Current medical guidelines generally recommend starting ART as soon as possible after your diagnosis, regardless of your CD4 count [3].

Important Exception: If you have certain opportunistic infections, particularly cryptococcal meningitis or tuberculosis meningitis, starting ART immediately can worsen your condition through Immune Reconstitution Inflammatory Syndrome (IRIS). In these specific situations, your HIV/OI team will carefully coordinate the timing of your ART. Never start, stop, or delay medication on your own.

The Foundation of Modern Treatment: INSTIs

Most people starting treatment today will begin with a regimen centered on a class of drugs called Integrase Strand Transfer Inhibitors (INSTIs) [1]. These drugs work by blocking integrase, an enzyme the virus uses to insert its genetic code into your own cells [3].

INSTIs—such as dolutegravir and bictegravir—are often the preferred starting point because they work quickly to lower your viral load and generally have fewer side effects than older HIV medications [4][5]. They also have a “high barrier to resistance,” meaning it is harder for the virus to mutate [6]. However, this does not mean that missing doses is safe; adherence remains essential with every regimen.

Customizing Your Treatment

Your doctor will choose your specific ART combination based on your unique health profile. This “individualized” approach ensures the medicine is safe for your organs and effective against your specific strain of the virus [7].

If you have… The Treatment Strategy usually involves… Why?
Hepatitis B (HBV) A regimen including two drugs that treat both HIV and HBV (often tenofovir plus emtricitabine) [8]. To prevent the Hepatitis B virus from becoming resistant or causing a “flare” in liver inflammation [9][10].
Kidney Disease An individualized choice between tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or a tenofovir-free regimen [11][12]. TDF can sometimes stress the kidneys; TAF is a newer version that has different impacts on kidney and bone health [13][14]. The best choice depends on eGFR and bone risk.
High Cholesterol Careful selection of statins or avoiding “boosted” HIV drugs (like those containing cobicistat) [15]. Some HIV medications can significantly increase the levels of statins in your blood, leading to muscle pain or injury [16].

The Vital Importance of Adherence

For ART to work, it must stay at a consistent level in your bloodstream. This is why adherence—taking your medication exactly as prescribed every day—is so important.

When you skip doses, the level of medication in your body drops. This gives the virus an “opportunity” to start replicating again (viral rebound) [17]. During this time, the virus can mutate, leading to drug resistance, where the medication no longer works to control the virus [18][19]. Research shows that adherence is absolutely critical to prevent treatment failure [20].

Missed Dose Plan: If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose. If you struggle with adherence due to side effects, cost, transportation, or housing, contact your clinic for support.

Watching for Drug Interactions

HIV medications are powerful and can interact with other substances in ways that make the ART less effective or increase side effects.

  • Supplements and Antacids: Common minerals like calcium, magnesium, iron, and zinc can bind to integrase inhibitors in your stomach, preventing your body from absorbing the HIV medicine [21][22]. The exact timing depends on the specific drug and whether it is taken with food, so you must ask your pharmacist for regimen-specific instructions [23].
  • Herbal Products: Some herbs, such as St. John’s Wort, can cause your body to process HIV drugs too quickly, leading to low drug levels and resistance [24].

Beyond the Daily Pill: Long-Acting Injectables

If you have documented virologic suppression on a stable regimen, no history of treatment failure, and no suspected resistance to the drugs, you may be eligible for long-acting injectable ART [25][26]. Instead of a daily pill, this treatment involves injections (usually cabotegravir and rilpivirine) given by a healthcare provider every one or two months [27].

While injectables offer freedom from daily pills, they require strict adherence to your appointment schedule. If you miss an injection, the “tail” of the drug can linger in your body at low levels, which is a high-risk scenario for developing resistance [28][29]. Your doctor will work with you to create an “oral bridging” plan (using pills) if you know you will miss an injection date [30]. Note that cabotegravir/rilpivirine does not treat Hepatitis B; people with active HBV need separate HBV-active therapy.

Common questions in this guide

When should I start antiretroviral therapy after an HIV diagnosis?
Most people are advised to start ART as soon as possible, regardless of their CD4 count. If you have cryptococcal meningitis or tuberculosis meningitis, starting immediately may cause a harmful inflammatory immune reaction called IRIS, so your HIV care team will set the timing. Do not start, stop, or delay ART without medical guidance.
What are integrase inhibitors, and why are they used for HIV treatment?
Integrase inhibitors block an HIV enzyme that the virus needs to insert its genetic material into human cells. Medicines such as dolutegravir and bictegravir are common starting options because they lower the viral load quickly and are generally well tolerated. They still need to be taken exactly as prescribed because missed doses can lead to treatment failure and resistance.
What should I do if I miss an ART dose?
Take the missed dose as soon as you remember unless it is almost time for your next dose. Do not take a double dose. If missed doses are connected to side effects, cost, transportation, housing, or another barrier, contact your clinic for support.
Can antacids, vitamins, or herbal products interfere with ART?
Yes. Calcium, magnesium, iron, and zinc can bind to some integrase inhibitors and reduce how much medicine your body absorbs. St. John’s Wort can also lower levels of some HIV medicines, and the correct timing for supplements depends on your regimen, so ask your pharmacist before using them.
How can hepatitis B or kidney disease affect my HIV medication choices?
People with hepatitis B often need an HIV regimen containing two medicines that also treat hepatitis B, commonly tenofovir with emtricitabine. Kidney function and bone health help determine whether tenofovir disoproxil fumarate, tenofovir alafenamide, or a tenofovir-free regimen is safest. Your clinician can use your eGFR and other health information to individualize the choice.
Who may be eligible for long-acting injectable HIV treatment?
Long-acting cabotegravir and rilpivirine may be considered for people with sustained viral suppression on a stable regimen, no history of treatment failure, and no suspected resistance to these medicines. Injections are given by a healthcare provider every one or two months, and keeping appointments is essential. This treatment does not treat hepatitis B, so people with active hepatitis B need separate hepatitis B-active therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which integrase inhibitor-based regimen is most appropriate for me given my initial lab results?
  2. 2.Since I am co-infected with Hepatitis B, how does my ART regimen ensure both viruses are being treated effectively?
  3. 3.Does my current kidney function (eGFR) affect which version of tenofovir (TDF or TAF) is safest for me?
  4. 4.Can you review all my current supplements and medications—including statins—to ensure there are no dangerous interactions with my ART?
  5. 5.Am I a candidate for long-acting injectable ART, and if not, what goals do we need to reach before I can switch?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (30)
  1. 1

    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.

    Gandhi RT, Bedimo R, Hoy JF, et al.

    JAMA 2023; (329(1)):63-84 doi:10.1001/jama.2022.22246.

    PMID: 36454551
  2. 2

    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

    Günthard HF, Saag MS, Benson CA, et al.

    JAMA 2016; (316(2)):191-210 doi:10.1001/jama.2016.8900.

    PMID: 27404187
  3. 3

    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

    Saag MS, Benson CA, Gandhi RT, et al.

    JAMA 2018; (320(4)):379-396 doi:10.1001/jama.2018.8431.

    PMID: 30043070
  4. 4

    Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

    Behrens GMN, Assoumou L, Liegeon G, et al.

    The Lancet. Infectious diseases 2026; (26(5)):510-521 doi:10.1016/S1473-3099(25)00681-4.

    PMID: 41344354
  5. 5

    HIV-1 3΄ polypurine tract mutations and integrase inhibitor resistance.

    Bishop MD, Xu L, Boyce CL, et al.

    AIDS (London, England) 2025; (39(14)):1996-2013 doi:10.1097/QAD.0000000000004315.

    PMID: 41603872
  6. 6

    Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.

    Engelman AN, Cherepanov P

    The FEBS journal 2021; (288(2)):427-433 doi:10.1111/febs.15438.

    PMID: 32506843
  7. 7

    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

    Saag MS, Gandhi RT, Hoy JF, et al.

    JAMA 2020; (324(16)):1651-1669 doi:10.1001/jama.2020.17025.

    PMID: 33052386
  8. 8

    Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia.

    Lui GC, Wong GL, Yang HC, et al.

    HIV medicine 2023; (24(10)):1035-1044 doi:10.1111/hiv.13545.

    PMID: 37735948
  9. 9

    Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.

    Gu L, Han Y, Li Y, et al.

    PloS one 2015; (10(8)):e0134539 doi:10.1371/journal.pone.0134539.

    PMID: 26288093
  10. 10

    Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.

    Hawkins C, Kang M, Bhattacharya D, et al.

    AIDS (London, England) 2022; (36(7)):975-984 doi:10.1097/QAD.0000000000003193.

    PMID: 35165216
  11. 11

    Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

    Mocroft A, Lundgren JD, Ross M, et al.

    The lancet. HIV 2016; (3(1)):e23-32.

    PMID: 26762990
  12. 12

    Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.

    Tao X, Lu Y, Zhou Y, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020; (93()):108-117 doi:10.1016/j.ijid.2020.01.035.

    PMID: 31988012
  13. 13

    Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

    Mills A, Crofoot G, McDonald C, et al.

    Journal of acquired immune deficiency syndromes (1999) 2015; (69(4)):439-45 doi:10.1097/QAI.0000000000000618.

    PMID: 25867913
  14. 14

    Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.

    Sarowar A, Coffin CS, Fung S, et al.

    Journal of acquired immune deficiency syndromes (1999) 2022; (91(4)):368-372 doi:10.1097/QAI.0000000000003079.

    PMID: 36288543
  15. 15

    The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy.

    Nhean S, Tseng A, Back D

    Current opinion in HIV and AIDS 2021; (16(6)):292-302 doi:10.1097/COH.0000000000000701.

    PMID: 34459470
  16. 16

    Pharmacokinetic drug interactions of integrase strand transfer inhibitors.

    Lu CH, Bednarczyk EM, Catanzaro LM, et al.

    Current research in pharmacology and drug discovery 2021; (2()):100044 doi:10.1016/j.crphar.2021.100044.

    PMID: 34909672
  17. 17

    Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality.

    Glass TR, Sterne JA, Schneider MP, et al.

    AIDS (London, England) 2015; (29(16)):2195-200 doi:10.1097/QAD.0000000000000782.

    PMID: 26544582
  18. 18

    Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis.

    Lailulo Y, Kitenge M, Jaffer S, et al.

    Systematic reviews 2020; (9(1)):292 doi:10.1186/s13643-020-01524-1.

    PMID: 33308294
  19. 19

    Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.

    Llibre JM, Ripamonti D, Geretti AM, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026; (82(5)):785-798 doi:10.1093/cid/ciaf471.

    PMID: 40985680
  20. 20

    Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.

    Haberer JE, Musinguzi N, Boum Y, et al.

    Journal of acquired immune deficiency syndromes (1999) 2015; (70(4)):386-92 doi:10.1097/QAI.0000000000000737.

    PMID: 26110445
  21. 21

    HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir.

    Rock AE, DeMarais PL, Vergara-Rodriguez PT, Max BE

    Infectious diseases and therapy 2020; (9(3)):691-696 doi:10.1007/s40121-020-00307-4.

    PMID: 32623580
  22. 22

    Use of dietary supplements containing polyvalent cations and antacids among people with HIV and its impact on viral suppression.

    Peng AT, Huang SH, Sun HY, et al.

    AIDS (London, England) 2021; (35(12)):2054-2057 doi:10.1097/QAD.0000000000002967.

    PMID: 34074818
  23. 23

    Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

    Engelman AN

    The Journal of biological chemistry 2019; (294(41)):15137-15157 doi:10.1074/jbc.REV119.006901.

    PMID: 31467082
  24. 24

    Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.

    Bettonte S, Berton M, Stader F, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023; (76(7)):1225-1236 doi:10.1093/cid/ciac901.

    PMID: 36377436
  25. 25

    Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.

    Hodge D, Back DJ, Gibbons S, et al.

    Clinical pharmacokinetics 2021; (60(7)):835-853 doi:10.1007/s40262-021-01005-1.

    PMID: 33830459
  26. 26

    Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.

    Sension MG, Brunet L, Hsu RK, et al.

    Infectious diseases and therapy 2023; (12(12)):2807-2817 doi:10.1007/s40121-023-00890-2.

    PMID: 37966701
  27. 27

    Eligibility for Intramuscular Cabotegravir/Rilpivirine in HIV-Positive Patients: An Observational Study.

    Martínez-Orea G, Rodríguez-Lucena FJ, Fuentes-Hidalgo F, et al.

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2025; (41(4)):159-164 doi:10.1177/87551225251333698.

    PMID: 40352251
  28. 28

    One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study.

    Muccini C, Gianotti N, Diotallevi S, et al.

    Open forum infectious diseases 2024; (11(7)):ofae326 doi:10.1093/ofid/ofae326.

    PMID: 38962526
  29. 29

    The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study.

    Han N, Loosli T, Anderegg N, et al.

    The Lancet. Global health 2025; (13(12)):e2133-e2143 doi:10.1016/S2214-109X(25)00350-X.

    PMID: 41240951
  30. 30

    Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis.

    Perez Navarro A, Nutt CT, Siedner MJ, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025; (81(2)):274-285 doi:10.1093/cid/ciae631.

    PMID: 39724249

This page explains ART choices, adherence, and medication safety for HIV and AIDS for informational purposes only and does not constitute medical advice. Ask your HIV care team before starting, stopping, or changing treatment.

Get notified when new evidence is published on AIDS.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.